Bioequivalence of a New Sublingual and a Reference Alprazolam Immediate Release Tablet Formulation

Open-Label, Randomized, Single-Dose, 2-Way Crossover Bioequivalence Study Comparing A New Alprazolam Sublingual Tablet Formulation To A Reference Alprazolam Immediate Release Tablet

This study tests the assumption that the bioavailability of alprazolam from a new sublingual formulation is the same as that from an existing commercial immediate release tablet formulation.

Inclusion Criteria:

• Healthy male or female subjects
• BMI 17.5 - 30.5
• Must provide informed consent

Exclusion Criteria:

• Clinically significant disease
• Narrow angle glaucoma
• Positive drug screen